ACADIA Pharmaceuticals Inc. (ACAD)
ACAD Price and Sentiment
ACAD Latest news
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.
Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.
Acadia was blindsided by NUPLAZID's CRL for treating hallucinations and delusions linked with dementia-related psychosis “DRP”. The loss of all expected near-term DRP sales chopped the share price in half. COVID-19 has hurt in-person patient office visits, which has hindered commercial growth. However, the company was able to find some encouraging trends in their Q2 earnings results.
Acadia Healthcare (ACHC) continues to gain from top-line growth, solid demand for behavioral health services, several growth-related initiatives and reducing debt levels.
We believe that Acadia Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around $17 levels currently and it is, in fact, down 64% from its pre-Covid high of around $47 in February 2020.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 16th Annual BioPharma Virtual Conference Fireside Chat Presentation: Friday, September 10, 2021 at 11:35 a.m. Eastern Time Morgan Stanley Virtual 19th Annual Global Healthcare Conference Fireside Chat Presentation: Monday, September 13, 2021 at 11:45 a.m. Eastern Time 2021 Cantor Virtual Global Healthcare Conference Fireside Chat
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia's interim Chief Financial Officer. The company is conducting a formal search for a new CFO. “On behalf of all of us at Acadi
Acadia Healthcare (ACHC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.